Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.82
+$0.16 · +1.85%
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Latest quote
$8.82
+$0.16 · +1.85%
After-hours
$8.82
$0.00 · 0.00%
Oct 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Day range
Current $8.82
52-week range
Current $8.82
Regular session · ET · Market data may be delayed.
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Day range
Current $8.82
52-week range
Current $8.82
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (SEK) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.82M SEK | 109.35M SEK | — | — | — |
| Cost of goods sold | — | — | — | — | 3.58M SEK |
| Gross profit | 3.82M SEK | 109.35M SEK | — | — | −3.58M SEK |
| Research and development | 390.35M SEK | 249.26M SEK | 276.29M SEK | 249.97M SEK | 30.05M SEK |
| Selling, general, and administrative | 67.91M SEK | 50.44M SEK | 44.6M SEK | 37.53M SEK | 2.39M SEK |
| Operating expenses | 458.26M SEK | 299.71M SEK | 321.51M SEK | 290.73M SEK | 32.59M SEK |
| Interest income | 23.89M SEK | 21.08M SEK | 10.54M SEK | 913K SEK | 70.2K SEK |
| Interest expense | 60K SEK | 8K SEK | 2K SEK | 8K SEK | — |
| Depreciation and amortization | — | 2.24M SEK | 3.42M SEK | 3.61M SEK | 3.38M SEK |
| Operating income | −454.45M SEK | −190.36M SEK | −321.51M SEK | −290.73M SEK | −32.59M SEK |
| Net income | −477.47M SEK | −168.63M SEK | −310.94M SEK | −288.42M SEK | −294.97M SEK |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
